Detalles de la búsqueda
1.
CAG (cytarabine, aclarubicin and granulocyte colony-stimulating factor) regimen for core binding factor acute myeloid leukaemia with measurable residual disease.
Ann Hematol
; 102(7): 1731-1738, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37145324
2.
Successful treatment of plasma exchange-refractory thrombotic thrombocytopenic purpura with rituximab: A case report.
World J Clin Cases
; 8(12): 2617-2622, 2020 Jun 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-32607340
3.
Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
Leuk Lymphoma
; 57(6): 1311-8, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26372888
4.
Long-term remission induced by low-dose rituximab for relapsed and refractory thrombotic thrombocytopenic purpura: A report of two cases.
Exp Ther Med
; 10(6): 2295-2298, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26668631
5.
Hemolytic anemia as first presentation of Wilson's disease with uncommon ATP7B mutation.
Int J Clin Exp Med
; 8(3): 4708-11, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26064408
Resultados
1 -
5
de 5
1
Próxima >
>>